Mike Pavia, Paul von Hoegen, Erwin Chargaff

Jul 08, 2002

Premium

Millennium Pharmaceuticals’ chief technology officer, Mike Pavia, is leaving the company after five years to become entrepreneur-in-residence at Oxford Bioscience Partners.

“It’s time to go out and help incubate the next generation of technologies,” Pavia said in an e-mail to ProteoMonitor’s sister publication GenomeWeb. Pavia will remain a consultant to Millennium.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Laureates Warn Against Hard Brexit

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

For All

Vox reports on inequities in genetic research and efforts to address them.

Lawrence Krauss to Retire Following Sexual Misconduct Allegations

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

This Week in PNAS

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Featured White Papers

A Mammalian System for Antibody/Protein Library Screening

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Main menu